A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours

NCT03468426 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

252

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-squamous, Non-Small-Cell Lung Cancer
Neoplasms

Interventions

DRUG: BI 836880
DRUG: Ezabenlimab

Sponsor

Boehringer Ingelheim